Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 51655-432

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 51655-432). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 432 52)

Label (51655 432 52)
This is a prescription medication with National Drug Code 51655-432-52. The medication is Alfuzosin Hydrochloride Extended-Release Tablets, which contain 10mg of active ingredient. Each bottle contains 30 tablets. The usage and dosage information is not available from the given text.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
The given text appears to be a part of a scientific study report. It includes a table showing the effect of placebo and Alfuzosin hydrochloride extended-release tablets on the IPSS total symptom score in a trial of 84 days. The data shows significant reduction in symptoms in the group taking Alfuzosin hydrochloride. No further information is available for evaluation.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The figure 4 represents the mean change in IPSS Total Symptom Score in Trial 3 after 28 and 56 days of treatment with Aituzosin hydrochloride extended-release tablets compared to Placebo with a statistically significant difference (p<0.01) between the two groups.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
The text provides statistical data related to the mean change from baseline in peak urine flow rate (mL/s) for a drug trial featuring a placebo group (N=167) and a group treated with alfuzosin hydrochloride extended-release tablets (N=170). The values are shown in a graph and there is a significant difference between the two groups. There is no additional information available.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
This is a graph showing the mean change from baseline in peak urine flow rate in Trial 2. The graph shows results for individuals taking Atuzosin hydrochloride extended-release tablets compared to a placebo group. There were 136 participants in the Atuzosin group and 147 in the placebo group. The graph shows that there was a statistically significant improvement in peak urine flow rate in the Atuzosin group compared to the placebo group. Days of treatment are plotted on the x-axis, and peak urine flow rates in mL/s are plotted on the y-axis.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
The text describes the results of a clinical trial (Trial 3) comparing the effects of a placebo (N=150) versus Alfuzosin hydrochloride extended-release tablets (N=151) on peak urine flow rate. The figure shows the mean change from baseline in peak urine flow rate (in mL/s) over a treatment period of 84 days. The statistical analysis indicated that there was no significant difference (NS) between the two treatments (p > 0.05).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.